Headline
The latest stories from AHA Today.
Drug maker Eli Lilly and Company said its neutralizing antibodies cocktail of bamlanivimab and etesevimab combine to significantly reduce hospitalizations and deaths attributed to COVID-19.
Regeneron Pharmaceuticals Inc. announced interim data indicating that its REGEN-COV antibody cocktail could be used as a passive vaccine to prevent COVID-19.
The public health emergency will likely remain in place through 2021, and the administration will give states 60 days’ notice before it decides to terminate the emergency or let it expire.
The Food and Drug Administration reissued emergency use authorizations for 10 systems authorized to decontaminate certain N95 respirators.
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed.
AHA today urged the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and “replace it with a serious effort at drug pricing reform.”
An estimated one in five people in the United States had a sexually transmitted infection at some point in 2018, with almost half of new infections in those under age 25, the Centers for Disease Control and Prevention reported.
In this Members in Action podcast, Julia Resnick, AHA senior program manager, speaks with leaders from CHI Health’s Creighton University Medical Center about how a culture enabled by interdisciplinary care teams is improving value for their patients.
As COVID-19 surges continue, lessons learned by health systems large and small reveal the importance of teamwork, communication, flexibility, preparation and supporting the physical and mental health of all staff.
The Commonwealth Fund issued a report outlining recommendations for federal investments in health.